[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Tajikistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100647882","scaf-tb---saving-children-and-their-families-from-tuberculosis-implementation-research-to-improve-tb-preventive-treatment-initiation-and-completion-rates-among-contact-persons-in-tajikistan-and-tanzania-100647882",false,"NCT07714707","SCAF-TB - Saving Children and Their Families From Tuberculosis: Implementation Research to Improve TB Preventive Treatment Initiation and Completion Rates Among Contact Persons in Tajikistan and Tanzania","SCAF-TB","Inclusion Criteria:\n\n* Contact persons (household and close contacts as defined by country guidelines) of people newly diagnosed with bacteriologically confirmed pulmonary TB disease (or as defined per national guidelines). National guidelines will determine whether we could include both contacts of index patients with drug-susceptible TB and drug-resistant TB.\n* Age ≥5 years\n* Able to provide written informed consent or assent.\n\nExclusion Criteria:\n\n* • Confirmed TB disease (evidenced by symptoms and\u002For clinical exam findings and\u002For chest radiographic findings suggestive of TB, positive mycobacterial culture or molecular TB testing or currently on TB treatment for TB disease)\n\n  * Likely to move outside the study area during the study period\n  * People already on TPT at time of recruitment\n  * Contra-indication for TPT:\n\n    * Known sensitivity or intolerance to isoniazid or rifamycins\n    * Suspected acute hepatitis or known chronic or unstable liver disease\n    * Alanine aminotransferase (ALT) \\> 3 times the upper limit of normal (ULN)\n    * Total bilirubin \\> 2.5 times the ULN\n    * On contra-indicated medications (as per national guidelines)\n  * Contra-indication for SIILTIBCY:\n\n    * Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 of SIILTIBCY Product Information.\n    * Hypersensitivity to Lactococcus lactis.\n    * Severe local or systemic reaction to other Mycobacterium tuberculosis derived products\n    * Any vaccination within the last 4 weeks\n  * Contra-indication for AudibleHealth:\n\n    * Having any condition making someone cannot cough voluntarily:\n\nHaving aphasia Having a medical history of cribriform plate injury or cribriform plate surgery, diaphragmatic hernia, external beam neck\u002Fthroat \u002F maxillofacial radiation, phrenic nerve injury\u002Fpalsy, radical neck\u002Fthroat \u002F maxillofacial surgery, vocal cord trauma or nodules Having patent tracheostomy stoma\n\nWithin the past year, had:\n\nacute traumatic injury to the head, neck, throat, chest, abdomen, or trunk Chest\u002Fabdomen \u002F trunk trauma or surgery, Intracranial surgery Neurovascular injury Neurovascular surgery",true,"ALL","5 Years",{"count":20,"type":21},880,"ESTIMATED","INTERVENTIONAL",[24],"NA","The SCAF-TB study aims to evaluate how the WHO-endorsed SIILTIBCY skin test can be best implemented to test close contacts for tuberculosis infection (TBI) in Tajikistan and Tanzania, either facility-based or home-based delivered by community health workers (CHWs) with or without AI-facilitated diagnostic tools.\n\nThe overall goal of this study is to improve access to innovative tuberculosis (TB) preventive services among children and their families in Tanzania and Tajikistan, both settings with a high burden of TB. Persons in close contact with people diagnosed with bacteriologically confirmed TB disease will be identified through the index patient and home visits. They will decide the preferred location for TBI testing, either at home or at the facility. Community health workers will be trained to implement home-based TB prevention services, including TBI testing and AI-assisted reading, and ruling out TB disease using a cough app (along traditional screening practices).\n\nThe main objectives of the study are:\n\n1. To assess whether CHWs can reliably measure SIILTIBCY results in TB contact persons at their homes, with or without the support of AI-assisted reading tools.\n2. To determine how feasible and acceptable it is for CHWs to perform home-based SIILTIBCY testing, both with and without AI assistance.\n3. To assess the added value, feasibility, and acceptability of using a mobile cough screening application, administered by CHWs, to help rule out TB disease.\n4. To evaluate the impact of these home-based TBI testing strategies on improving uptake and completion of TB preventive treatment (TPT), as well as their budget implications for both the health care system and affected households.\n\nThe study will be conducted in primary health care facilities in Tajikistan and Tanzania, which have access to short-course TPT regimens. The study population is composed of persons in close contact with people diagnosed with bacteriologically confirmed TB disease, and eligible for TPT as per national guidelines.\n\nThe main outcomes of interest are:\n\n1. SIILTIBCY inter-reader agreement CHW (home-based) and HCW (facility-based)\n2. SIILTIBCY inter-reader agreement CHW with AI reading and without AI reading\n3. Proportion tested for TBI out of those eligible for TBI testing\n4. Proportion tested positive for TBI, stratified by demographic characteristics and mode of delivery\n5. Diagnostic agreement between a cough application and symptom screening\n6. Proportion initiated on TPT out of those eligible for TPT, stratified by regimen and mode of testing\n7. Proportion completing TPT out of those initiated on TPT, stratified by regimen and mode of testing.\n8. Interest-holders' perspectives on home-based TBI testing and cough app screening.\n9. Budgetary impact scaling-up home-based TBI testing and cough app screening",[27,28,29],"Tuberculosis Infection, Latent","Tuberculosis Active","TPT",[31,32,33,34,35,36,37,38,39],"AI tools","Contact investigation","Tuberculosis Preventive Treatment","Tanzania","kyrgyzstan","community health care","AI (Artificial Intelligence)","Cough screening App","SIILTIBCY","NOT_YET_RECRUITING","2026-07-14",{"date":43,"type":44},"2026-07-20","ACTUAL",{"date":46,"type":21},"2026-06",{"date":48,"type":21},"2028-03",{"name":50,"class":51},"KNCV Tuberculosis Foundation","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100483779","expanding-medication-assisted-therapies-in-central-asia-100483779","NCT05579470","Expanding Medication-Assisted Therapies in Central Asia","ExMAT CA","Inclusion Criteria:\n\ni. Aim 1: The inclusion criteria for Aim 1 Consists of:\n\n1. Quantitative surveys for PWID\n\n   1. 18 years or older\n   2. Meeting DSM-V criteria for opioid dependence\n   3. Be either treatment naïve and seeking OAT or be on OAT for \\\u003C 90 days\n2. Organizational Assessments for OAT Delivery Staff\n\n   1. 18 years or older\n   2. Currently working as an OAT delivery professional at an OAT delivery site\n3. Focus Groups (PWID on OAT)\n\n   1. 18 years or older\n   2. Meeting DSM-V criteria for opioid dependence\n   3. Be either treatment naïve and seeking OAT or be on OAT for \\\u003C 90 days\n4. Focus Groups (PWID not on OAT)\n\n   1. 18 years or older\n   2. Meeting Diagnostic and Statistical Manual of Mental Disorders(DSM)-V criteria for opioid dependence\n   3. Be OAT naïve (defined as never having been on OAT or having not received treatment for \\> 1 year)\n5. Focus Groups (OAT delivery staff)\n\n   1. 18 years or older\n   2. Currently working as an OAT delivery professional at an OAT delivery site\n\nii. Aim 2: The inclusion criteria for Aim 2 consists of:\n\n1. 18 years or older\n2. Currently assigned as a Chief Narcologist for an Oblast\n\niii. Aim 3: The inclusion criteria for Aim 3 consists of:\n\n1. 18 years or older\n2. Authorized as a professional to work at an OAT delivery site\n\nExclusion Criteria:\n\n* Not willing to provide consent","18 Years",{"count":62,"type":21},900,[24],"Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (OAT) in this region is the most cost-effective strategy to prevent new HIV infections, and more effective when combined with antiretroviral therapy (ART). The investigators propose to use the Network for the Improvement of Addiction Treatment (NIATx) implementation strategy to scale-up OAT in three diverse Central Asian countries (Kazakhstan, Kyrgyzstan, Tajikistan) and guided by the Exploration-Planning-Implementation-Sustainment (EPIS) framework. Understanding the trajectories of implementation and scale-up in this context may emerge through creating communities of practice, especially when cohesion and competence evolves, and may guide other healthcare delivery challenges in the region (e.g., HIV, TB); as well as build important regional expertise and understanding implementation trajectories should help support OAT program sustainability.",[66],"Opioid Use Disorder",[68,69,70,71],"HIV","OUD","OAT","Central Asia","RECRUITING","2025-09-16",{"date":75,"type":44},"2025-09-22",{"date":77,"type":44},"2023-08-07",{"date":79,"type":21},"2026-12-31",{"name":81,"class":51},"Yale University",4,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100590024","pride-iii-prison-interventions-and-hiv-prevention-collaboration-100590024","NCT06962033","PRIDE III Prison Interventions and HIV Prevention Collaboration","PRIDE III","Inclusion Criteria:\n\nAim 1:\n\n1. Quantitative surveys for prison OAT providers\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation OAT provider for a probation site\n2. ECHO procedures\n\nAim 2:\n\n1. Quantitative surveys for people in probation\n\n   * Being 18 years or older\n   * Screen yes to opioid injection on the online screener questionnaire\n   * Currently in probation\n2. Quantitative surveys for probation and prison officers\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation or prison officer at a probation site\n3. Focus Groups (People in probation)\n\n   * Being 18 years or older\n   * Screen yes to opioid injection criteria on the online screener\n   * Currently in probation\n4. Focus Groups (Probation and prison officers)\n\n   * Being 18 years or older\n   * Being currently assigned and working as a probation or prison officer at a probation\n   * Has more than 3 months of field experience\n   * Works at a probation site within 25 kilometers of an OAT site\n\nExclusion Criteria:\n\n\\-",{"count":91,"type":21},300,[24],"The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).",[95,96],"Hiv","Opioid Use","2025-05-08",{"date":99,"type":44},"2025-05-11",{"date":101,"type":44},"2024-11-05",{"date":103,"type":21},"2028-12",{"name":81,"class":51},5,""]